Repurposing Approved Drugs for Sarcopenia Based on Transcriptomics Data in Humans
Sarcopenia, characterized by age-related loss of muscle mass, strength, and decreased physical performance, is a growing public health challenge amid the rapidly ageing population. As there are no approved drugs that target sarcopenia, it has become increasingly urgent to identify promising pharmaco...
Enregistré dans:
Auteurs principaux: | Shuang Liang (Auteur), Danyang Liu (Auteur), Zhengwu Xiao (Auteur), Jonathan Greenbaum (Auteur), Hui Shen (Auteur), Hongmei Xiao (Auteur), Hongwen Deng (Auteur) |
---|---|
Format: | Livre |
Publié: |
MDPI AG,
2023-04-01T00:00:00Z.
|
Sujets: | |
Accès en ligne: | Connect to this object online. |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
par: Dan-Yang Liu, et autres
Publié: (2021) -
Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review
par: Bruno Silva Andrade, et autres
Publié: (2020) -
Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema
par: Fieke M. Rosenberg, et autres
Publié: (2024) -
A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments
par: Xiao-Hua Li, et autres
Publié: (2023) -
Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
par: Abdulaziz L, et autres
Publié: (2022)